BC
JAZZ icon

Bayforest Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bayforest Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55K Sell
291
-1,159
-80% -$203K 0.06% 534
2025
Q4 		$247K Sell
1,450
-280
-16% -$42.9K 0.18% 216
2025
Q3 		$228K Sell
1,730
-4,061
-70% -$487K 0.11% 354
2025
Q2 		$615K Buy
5,791
+3,996
+223% +$434K 0.27% 122
2025
Q1 		$223K Buy
+1,795
New +$234K 0.1% 369

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bayforest Capital's JAZZ Position: Q1 2026 in Review

Bayforest Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 80% in Q1 2026, selling an estimated $203K and leaving 291 shares worth $55K. The position accounts for 0.06% of the portfolio, ranked #534.

Bayforest Capital first reported a position in JAZZ in Q1 2025 and has held it in 5 quarters since. The position peaked at $615K in Q2 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Bayforest Capital held 291 shares of Jazz Pharmaceuticals worth $55K as of Q1 2026.
  • Bayforest Capital sold 1,159 Jazz Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Jazz Pharmaceuticals made up 0.06% of Bayforest Capital's portfolio in Q1 2026, its #534 holding.
  • Bayforest Capital first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Bayforest Capital's Jazz Pharmaceuticals position peaked at $615K in Q2 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.